![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis
|
|
|
Reported by Jules Levin
APASL 2017 Feb 15-19, Shanghai, China
Lai Wei1, Guiqiang Wang2, Yan Luo3, Chi-Jen Chu4, Seung Woon Paik5, Jinlin Hou6, Jun Cheng7, Qing Xie8, Zhongping Duan9, Jia-Horng Kao10, Bo Fu3, Sarah Kopecky-Bromberg3, Niloufar Mobashery3, and Jeong Heo11 1Peking University Peoples Hospital, Beijing; 2Peking University First Hospital, Beijing; 3AbbVie Inc., North Chicago, IL; 4Taipei Veterans General Hospital, Taipei City; 5Samsung Medical Center, Sungkyunkwan University, Seoul; 6Nanfang Hospital of Southern Medical University, Guangzhou; 7Beijing Di Tan Hospital, Capital Medical University, Beijing; 8Ruijin Hospital Shanghai Jiaotong, University School of Medicine, Shanghai; 9Beijing Youan Hospital Capital Medical University, Beijing; 10National Taiwan University Hospital, Zhongzheng District; 11Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan
![0221171](../images/022317/022117-5/0221171.gif)
![0221172](../images/022317/022117-5/0221172.gif)
![0221173](../images/022317/022117-5/0221173.gif)
![0221174](../images/022317/022117-5/0221174.gif)
![0221175](../images/022317/022117-5/0221175.gif)
![0221176](../images/022317/022117-5/0221176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|